Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
September 24, 2024
Takeda Oncology: Decades of Leadership in Oncology | Takeda Oncology
Decades of Leadership in Oncology
Oncology Pipeline
Discovering and developing innovative therapies to deliver potentially transformative treatments
About Takeda Oncology
Our Viewpoints
Living is More Than Surviving: Balancing Clinical Outcomes with Patient Impact
Over the past several decades, the rapid pace of scientific advancement has catalyzed a revolution in the way we treat cancers. Takeda Oncology │ Leadership │ Article
